Analytical testing will accelerate Numinus'
Research and Development capabilities and generate revenue through
third-party clients
VANCOUVER, BC, Nov. 29, 2021 /CNW/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader
in psychedelics-focused mental healthcare, has today announced
novel, proprietary methods for psychedelic mushroom compound
screening. The testing, which was developed and validated in-house,
will be available as part of its service offerings for third-party
clients and used for evidence-based conversations with the
regulators.
As a global leader in psychedelics testing Numinus Bioscience
continues to make strides in the development of analytical testing
methods for the psychedelics industry. Amongst the matrices for
which methodologies are being developed are Psilocybe
mushroom fruiting bodies, extracts, and derivatives and, coupled
with required testing such as contaminants and residues, the lab
has validated methods for active constituents. The
Psilocybe mushrooms constituent screen includes Psilocybin,
Psilocin, Baeocystin, Norbaeocystin and Tryptophan, Norpsilocin and
Aeruginascin which represent the most well-defined alkaloids for
Psilocybe species.
"The testing we've developed and validated at Numinus Bioscience
will facilitate the safety and efficacy testing of psychedelics for
our products, our clients and strategic partners, and ultimately
the industry," says Sharan Sidhu,
Science Officer and General Manager. "Working with regulators, we
look forward to establishing tools to create a stronger foundation
of analytical methods for psychedelic compounds and products."
In addition to screening for therapeutically active
constituents, the lab has successfully developed a psychedelic
mushroom toxicity screen that includes nephrotoxic and hepatotoxic
compounds. Although the platform has been developed for industry,
the screen can quickly identify toxins from several varied species
and is being offered to healthcare providers to identify toxins in
poison control responses, demonstrating the value of this research
beyond the psychedelic industry. Toxicity scans are completed
using the Orbitrap, a state-of-the-art, industry leading high
resolution mass spectrometry instrument.
"These in-house validated methods are another example of success
in analytical development at Numimus, showing our commitment to
strengthen regulatory confidence in these products," says
Payton Nyquvest, CEO and Founder,
Numinus. "We continue to push the boundaries as we establish our
role as The Center of Excellence for Psychedelic Research and
Development, with the furtherment of the industry at the heart of
our advancements."
The research team has thus far characterized over 260 compounds,
many of them characterized for the first time in psychedelic
mushrooms and continues to make novel discoveries in research and
development of Psilocybin. Numinus Bioscience also continues to
build testing capabilities for Ketamine, LSD, Mescaline, DMT and
MDMA.
About Numinus
Numinus Wellness (TSXV: NUMI) helps
people to heal and be well through the development and delivery of
innovative mental health care and access to safe, evidence-based
psychedelic-assisted therapies. The Numinus model - including
psychedelic production, research and clinic care - is at the
forefront of a transformation aimed at healing rather than managing
symptoms for depression, anxiety, trauma, pain and substance use.
At Numinus, we are leading the integration of psychedelic-assisted
therapies into mainstream clinical practice and building the
foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn,
Facebook, Twitter, and Instagram.
Forward-looking statements
This press release
contains forward-looking statements within the meaning of
applicable securities laws. All statements that are not
historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs
regarding future performance are "forward-looking
statements". Forward-looking statements can be identified by
the use of words such as "expects", "does not expect", "is
expected", , "intends", "anticipates", "does not anticipate",
"believes" or variations of these words, expressions or statements,
that certain actions, events or results "may", "could", "would",
"might" or "will be" taken, will occur or will be
realized. Such forward-looking statements involve risks,
uncertainties and other known and unknown factors that could cause
actual results, events or developments to differ materially from
the results, events or developments expected and expressed or
implied in such forward-looking statements. These risks and
uncertainties include, but are not limited to, dependence on
obtaining and maintaining regulatory approvals, including the
acquisition and renewal of federal, provincial, municipal, local or
other licenses, and any inability to obtain all necessary
government authorizations, licenses and permits to operate and
expand the Company's facilities; regulatory or policy changes
such as changes in applicable laws and regulations, including
federal and provincial legalization, due to fluctuations in public
opinion, industry perception of integrative mental health,
including the use of psychedelic-assisted therapy, delays or
inefficiencies or any other reason; any other factor or
development likely to hamper the growth of the market; the
Company's limited operating and profitability track
record; dependence on management; the Company's need for
additional financing and the effects of financial market conditions
and other factors on the availability of
capital; competition, including that of more established
and better funded competitors; the continued impact of the
COVID-19 pandemic; and the need to build and maintain alliances and
partnerships, including with research and development companies,
customers and suppliers. These factors should be carefully
considered, and readers are cautioned not to place undue reliance
on forward-looking statements. Despite the Company's efforts
to identify the main risk factors that could cause actual measures,
events or results to differ materially from those described in
forward-looking statements, other risk factors may cause measures,
events or developments to materially differ from those anticipated,
estimated or intended. There can be no assurance that
forward-looking statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in forward-looking statements. The Company does
not undertake to revise forward-looking statements, even if new
information becomes available as a result of future events, new
facts or any other reason, except as required by applicable
laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this news release.
View original
content:https://www.prnewswire.com/news-releases/numinus-develops-proprietary-psychedelic-tests-with-new-toxicity-and-potency-scans-301432673.html
SOURCE Numinus Wellness Inc.